NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG - Schnaiter, Andrea Barbara; Paschka, Peter; Rossi, Marianna; Zenz, Thorsten; Bühler, Andreas; Winkler, Dirk; Cazzola, Mario; Döhner, Konstanze; Edelmann, Jennifer; Mertens, Daniel; Kless, Sabrina; Mack, Silja; et al. (Blood, 2013)
Gesehen am 12.07.2021